CAR-T cell therapy has demonstrated excellent efficacy in treating hematologic malignancies

The gap

Evidence profile

Sourced from the future work of the source papers, classified as general, spanning 4 journals. Those papers have been cited 10 times in total.

Supporting evidence — 6 representative gaps

• Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment (2026) · Drug Delivery and Translational Research · doi

  The future interface of nanotechnology, immunology, and data science holds promising opportunities to overcome the limitations and realize the full potential of silica nanocar- riers in cancer immunotherapy. Recent versions of silica nanocarriers are being developed to respond dynamically to tumor- or immune-specific cues, utilizing the properties of next-generation silica nanocarriers. Time- and space-depen- dent control of the delivery of immunotherapeutic payloads can be achieved using stimuli-responsive architectures, such as pH-, redox-, enzymatic-, or inflammation-sensitive archi- tectures. Such systems can enhance treatment synergy and minimize systemic toxicity, particularly with intricate com- bination immunotherapy regimens [179]. Immunoprofiling and tumor genomics are creating opportunities for the trend of personalized immunotherapy. Silica nanocarriers provide an adaptable platform for diverse therapeutic applications, including personalized cancer vaccines and tailored com- bination therapy. Silica nanocarriers can improve response rates and stability for clinical use by modulating a patient’s immune response through payload composition and release profiles. Machine learning and AI are emerging as viable tools for designing and optimizing nanocarriers [180]. Data-driven methods can be used to predict structure– function relationships, optimize formulation parameters, and select the most appropriate combinations of immuno- therapeutic agents, thereby reducing reliance on trial-and- error approaches and shortening the development time of silica nanocarriers, enhancing the efficiency of the transla- tion process. Subsequent patenting is more integrated and complex, encompassing multi-stimuli-responsive and adap- tive release systems, as well as AI-supported formulation systems. The innovation wave is anticipated to be highly innovative, with patents having high mechanistic rationality, clinical applicability, and manufacturability. Positioning in this highly competitive environment will be a key part of commercializing silica combination immunotherapies, leveraging strategic IP [181].

  generalfuture work
  Keywords: silica nanocarriers immunotherapy systems opportunities cancer tumor immune time stimuli responsive bination personalized therapeutic response
• Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions (2026) · Acta Pharmacologica Sinica · doi

  Cell-based immunotherapies have emerged as a central compo- nent of contemporary oncology by enabling therapeutic mechan- isms that are difficult to achieve with conventional modalities, functional adaptability within including in vivo expansion, dynamic tumor ecosystems, and the potential for durable immune surveillance [120]. The clinical success of CAR T-cell therapy in hematologic malignancies has validated this paradigm and catalyzed the development of a broader spectrum of cellular tumor- platforms, infiltrating lymphocytes, NK cell–based therapies, dendritic cell vaccines, and macrophage-directed strategies [121–123]. Collec- tively, these approaches expand the scope of precision immuno- oncology by engaging complementary immune functions, includ- ing antigen-specific cytotoxicity, innate effector activity, antigen presentation and repertoire shaping, and active modulation of the tumor microenvironment. encompassing TCR–engineered T Despite this progress, the principal limitations of the field are now well defined. Antigen escape and heterogeneous target expression continue to compromise response durability, particu- larly for single-antigen strategies [30]. In solid tumors, immune exclusion, suppressive myeloid programs, metabolic constraints, and physical barriers collectively limit cellular trafficking, persis- tence, and effector function, even in the presence of tumor- In parallel, manufacturing remains reactive immune cells [124]. both a biological and logistical bottleneck; variability in starting material, prolonged vein-to-vein timelines, and high production costs restrict scalability and broad clinical access [125, 126]. These challenges indicate that future advances will depend less on incremental refinement of individual platforms and more on integrated strategies that simultaneously address target recogni- tion, cellular fitness, tumor accessibility, and safety. Several development priorities are likely to shape the next phase of cellular immunotherapy. Multiplex targeting and logic-gated designs provide promising solutions to antigen escape while improving on-target specificity [127]. Cell-state engineering—supported by optimized manufacturing condi- tions, epigenetic and metabolic conditioning, and precise genome editing—offers a pathway to enhanced persistence and resistance to exhaustion [128, 129]. Off-the-shelf approaches, including allogeneic donor–derived products and iPSC–based platforms, have the potential to reduce production timelines and improve scalability, provided that immune rejection and product consistency can be effectively controlled [53, 130, 131]. rational combination strategies are increasingly In addition, essential; likely require coordinated interventions integrate immune improved trafficking, and tumor microenvironment priming, modulation while maintaining an acceptable therapeutic index [132]. for many solid tumors, durable efficacy will that Acta Pharmacologica Sinica (2026) 0:1 – 18

  generalfuture work
  Keywords: tumor immune cell antigen cellular strategies based platforms target oncology therapeutic including potential durable clinical
• Advanced strategies to enhance the safety, persistence, and efficacy of CAR-T cells in solid tumors (2026) · Frontiers in Immunology · doi

  CAR-T cell therapy has demonstrated excellent efficacy in treating hematologic malignancies, and CAR-T-based personalized immunotherapy has led to notable remissions. However, this mode of immunotherapy is still in its early stages, and specific challenges persist. For example, the CAR-T-associated CRS and neurotoxicity are significant side effects. Additionally, noteworthy factors include the limited persistence of CAR-T cells, their failure to home to tumor sites, inhibitory factors within the TME, exhaustion induced by metabolic stress, and inhibitory signals. Addressing these barri- ers will move the field one step closer to translating CAR-T cell therapy into a durable and widely applicable cancer treatment. Recent advances reviewed here highlight a shift toward rational, multi-layered engineering strategies. Self-regulating CAR designs and switch-on/switch-off CAR systems provide critical safety controls to mitigate CRS and neurotoxicity. Other strategies, such as integrating nanomaterials and OVs, offer powerful means to remodel the TME,

  generalfuture work
  Keywords: cell therapy immunotherapy neurotoxicity factors inhibitory strategies switch excellent cacy treating hematologic malignancies based personalized
• Adaptive resistance in cancer immunotherapy (2026) · Cellular and Molecular Immunology · doi

  Summary of key points Adaptive resistance to cancer immunotherapy refers to a dynamic, multifactorial process through which tumors evade immune destruction under therapeutic pressure. It manifests in two distinct clinical patterns: on-treatment progression driven by insufficient tumor-killing capacity and postremission relapse resulting from failure to establish or sustain durable antitumor immune memory. As a central challenge across diverse cancers, it critically limits long-term survival for most patients. This process is driven by dynamically evolving immunoediting, in which tumors deploy both intrinsic (e.g., antigen loss) and extrinsic (e.g., T-cell immunosuppressive TME) adaptations. To counter dysfunction, this challenge, a therapeutic paradigm is proposed to evolve from a model focused on tumor clearance to an intelligent strategy that restores immediate effector function while simultaneously guiding the immune system toward establishing long-lasting AIM. Emer- ging strategies rationally combine ICIs or ICT with agents that remodel the immunosuppressive TME, reprogram tumor metabo- lism, or promote optimal T-cell responses. The ability of next- generation therapeutic platforms to induce and sustain AIM warrants further in-depth investigation. Promising candidates include bispecific antibodies that costimulate memory pathways, personalized neoantigen vaccines designed to prime high-quality memory, and advanced engineered cellular therapies equipped with memory-like properties (e.g., stem-like or tissue-resident memory-like CAR-T cells or microenvironment-resistant CAR- T cells). The emphasis shifts from achieving immediate tumor eradication to achieving a functional cure, defined by immune- mediated disease control underpinned by the reversion of T-cell exhaustion and durable AIM.

  generalfuture work
  Keywords: memory immune tumor therapeutic cell like process tumors driven sustain durable challenge long immunosuppressive immediate
• Nanotechnology-enabled immunomodulation in esophageal cancer: targeting the tumor microenvironment to overcome therapeutic barriers (2026) · Frontiers in Immunology · doi

  Nanotechnology represents a highly promising paradigm for overcoming the immunosuppressive barriers that limit the efficacy of immunotherapy in esophageal cancer. The complex and dynamic TME, characterized by hypoxia, acidosis, dense ECM, and diverse immunosuppressive cell populations, presents multiple targets for nanotechnology-enabled intervention. Engineered nanocarriers can deliver therapeutic payloads with spatiotemporal precision, modu- late specific cellular populations, and reprogram the TME to support effective antitumor immunity. Significant progress has been made in developing nanomaterial including LNPs, polymeric platforms for TME modulation, nanoparticles, MSNs, metal-based nanoparticles, and biomimetic systems. These platforms can be engineered to respond to specific TME cues, enabling controlled drug release at tumor sites. The ability to co-deliver multiple therapeutic agents within a single nanocarrier allows for simultaneous targeting of different immuno- suppressive mechanisms, producing synergistic antitumor effects. Nanotechnology-enabled strategies for TME reprogramming include repolarization of TAMs, depletion of MDSCs, modulation of CAFs, restoration of DC function, alleviation of hypoxia and acidosis, and induction of ICD and ferroptosis. These approaches can convert the immunologically “cold” TME into a “hot” TME that supports T cell infiltration and effector function. Combination strategies that integrate nanomedicine with ICIs, photodynamic therapy, chemotherapy, radiotherapy, or CAR-T cell therapy offer the potential for enhanced therapeutic efficacy and durable antitu- mor immunity. Despite these promising advances, several challenges must be addressed before nanotechnology-enabled immunotherapy can be translated to clinical practice for esophageal cancer. Importantly, while a wealth of innovative nanoplatforms have shown remarkable success in modulating the TME of other solid tumors, a significant translational gap remains. Future research must prioritize the rigorous evaluation of these nanomedicines specifically within orthotopic and genetically engineered models of esophageal cancer to account for its unique physiological and immunological barriers. The heterogeneity of the TME between patients and within individual tumors necessitates personalized approaches that can adapt to specific TME characteristics (14, 21). The development of biomarkers for patient stratification and treatment monitoring is essential for optimizing therapeutic outcomes (21, 98). Scalable manufacturing processes and quality control measures must be established to ensure consistent production of nanomedicines (16, 113). The potential toxicity of nanomaterials, particularly metal- based nanoparticles, requires careful evaluation through compre- hensive preclinical and clinical studies (20, 113). Long-term bio- compatibility, biodegradability, and clearance mechanisms must be characterized to ensure patient safety (20, 113). The immunogenic- ity of nanoparticle components, including synthetic polymers and surface ligands, may trigger adverse immune responses that limit therapeutic efficacy (16, 113). Artificial intelligence and machine learning approaches offer opportunities for optimizing nanoparticle design and predicting therapeutic outcomes (106, 108, 114). AI-guided design can accel- erate the development of nanocarriers with optimal physicochem- ical properties for specific TME characteristics (106, 114). Integration of spatial proteomics and transcriptomics with nano- technology can provide insights into TME dynamics and guide personalized treatment strategies (98). Future research should focus on developing multifunctional nanoplatforms that can simultaneously monitor TME changes and deliver therapeutic interventions in a closed-loop manner (114, 115). Theranostic nanoparticles that combine imaging and thera- peutic capabilities can enable real-time assessment of treatment response and adaptive therapy (114, 115). The development of TME-responsive nanomedicines that can adapt their properties in response to dynamic changes in the TME represents an exciting frontier for precision cancer immunotherapy. In conclusion, nanotechnology-enabled immunomodulation represents a highly promising conceptual approach for overcoming therapeutic barriers in esophageal cancer. By targeting the

  generalfuture work
  Keywords: therapeutic nanotechnology cancer speci esophageal enabled nanoparticles must represents promising barriers cacy immunotherapy cell engineered
• CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies (2026) · Frontiers in Immunology · cited 10× · doi

  In the field of cellular immunotherapy, CAR-M, an emerging treatment method, has gradually shown great potential in tumor treatment. By integrating the innate immune characteristics of macrophages with synthetic biological modification strategies, the immunosuppressive TME can be reprogrammed, which provides a new paradigm for the treatment of solid tumors. Current studies have revealed multiple antitumor mechanisms involving the secretion of proinflammatory factors (such as TNF-a and IL-12), the induction of M1 polarization, and the enhancement of T-cell cross-presentation. However, the heterogeneity of cell sources, insufficient persistence in vivo and bottlenecks associated with large-scale production still need to be overcome. Future research on CAR-M cells is expected to focus on multiple dimensions. 1) Multimodal gene editing technology: CRISPR-Cas9 and base editing technology are used to target the metabolic pathway of CAR-M or integrate the suicide switch (iCasp9) to balance efficacy and safety; 2) microenvironment- responsive intelligent design: develop light-controlled, tissue- responsive, pH- or oxygen concentration-dependent CAR logic gate systems to achieve space-time specific activation; 3) interdisciplinary technology integration: combine single-cell transcriptome sequencing and an AI-driven CAR optimization platform to analyze the dynamic functional phenotype of CAR-M and predict treatment response; 4) clinical translation verification: multicenter clinical trials were conducted to evaluate the universality of CAR-M in heterogeneous tumors, and a standardized production quality control system was established. With the coordinated development of synthetic biology, computational immunology and precision medicine, CAR-Ms are expected to overcome the barriers associated with solid tumor treatment and become the core pillar of the next generation of tumor immunotherapy.

  generalfuture work
  Keywords: treatment tumor cell technology immunotherapy synthetic cation solid tumors multiple associated production overcome expected editing

Questions about this gap